Agenus Inc AGEN

Healthcare Biotechnology

Agenus Inc. is an immuno-oncology (I-O) company targeting cancer and infectious diseases with a pipeline of immunological agents. It is specialized in developing therapies to activate the body's immune system against cancer and infections. Its pipeline includes immune-modulatory antibodies, adoptive cell therapies (via MiNK Therapeutics, Inc.), and vaccine adjuvants (via SaponiQx, Inc.). Its primary focus is I-O, and its diverse pipeline is supported by its in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. Its most advanced antibody candidates are botensilimab (a multifunctional immune cell activator and human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody (AGEN1811)) and balstilimab (a programmed death receptor-1 (PD-1) blocking antibody). Its pipeline includes several classes of immunotherapies: checkpoint inhibitors, immune activators, and tumor microenvironment conditioning agents.

NDAQ:AGEN - Post by User

Agenus Inc

<< Previous

Bullboard Posts

Next >>

Post by zalmonellaon Apr 08, 2024 11:42pm

114 Views

Post# 35978167

No fun city

Great. One April 13 i will have 250 shares of this worthless stock for which I've paid over the years a total of $10,400. I'm not counting on seeing $42 a share anytime soon.

Hit me over the head again, Bob.

<< Previous

Bullboard Posts

Next >>

Apolo IV Acquisition and Marviken Ontario sign merger agreement